Advanced Healthcare Materials · 2019 · 150 citations · 39 references
PharmacyNeurosciencePharmaceuticsDrug DeliveryGene DeliveryNanoparticle Drug DeliveryBrain Targeted DeliveryIntracellular Drug DeliveryNanocarriers For TherapeuticsNucleic Acid DeliveryPlasmid Dna DeliveryProtein DeliveryDna NanocarriersExtracellular VesiclesGene Delivery To The BrainLysosomal Enzyme TargetingNanocarriersPlasmid Dna VectorsProtease-mediated Protein Degradation
Extracellular vesicles (EVs) are promising natural nanocarriers for delivery of various types of therapeutics. Earlier engineered EV-based formulations for neurodegenerative diseases and cancer are reported. Herein, the use of macrophage-derived EVs for brain delivery of a soluble lysosomal enzyme tripeptidyl peptidase-1, TPP1, to treat a lysosomal storage disorder, Neuronal Ceroid Lipofuscinoses 2 (CLN2) or Batten disease, is investigated. TPP1 is loaded into EVs using two methods: i) transfection of parental EV-producing macrophages with TPP1-encoding plasmid DNA (pDNA) or ii) incorporation therapeutic protein TPP1 into naive empty EVs. For the former approach, EVs released by pretransfected macrophages contain the active enzyme and TPP1-encoding pDNA. To achieve high loading efficiency by the latter approach, sonication or permeabilization of EV membranes with saponin is utilized. Both methods provide proficient incorporation of functional TPP1 into EVs (EV-TPP1). EVs significantly increase stability of TPP1 against protease degradation and provide efficient TPP1 delivery to target cells in in vitro model of CLN2. The majority of EV-TPP1 (≈70%) is delivered to target organelles, lysosomes. Finally, a robust brain accumulation of EV carriers and increased lifespan is recorded in late-infantile neuronal ceroid lipofuscinosis (LINCL) mouse model following intraperitoneal administration of EV-TPP1.
39
Exosomes as drug delivery vehicles for Parkinson's disease therapy
Matthew J. Haney, Natalia L. Klyachko, Yuling Zhao et al. · Journal of Controlled Release · 2015 · 2K citations · Full text
AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA
Teresa Fernandes‐Alnemri, Je‐Wook Yu, Pinaki Datta et al. · Nature · 2009 · 1.8K citations · Full text